ArticleExperimental and molecular pathology2012
Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma.
Article in Experimental and molecular pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- The Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.Journal of cancer science and clinical therapeutics · 2025Article
- VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification.Bioscience reports · 2024Article
- Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer.International journal of molecular sciences · 2022Review
- Comprehensive analysis of a new immune-related prognostic signature for esophageal cancer and its correlation with infiltrating immune cells and target genes.Annals of translational medicine · 2021Article
- Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.Journal of gastrointestinal cancer · 2019Observational
- Vitamin D and Gastrointestinal Cancers: A Narrative Review.Digestive diseases and sciences · 2019Review
- Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study.Oncotarget · 2018Article
- Vitamin D in esophageal cancer: Is there a role for chemoprevention?World journal of gastrointestinal oncology · 2018Review
- Bile salt receptor TGR5 is highly expressed in esophageal adenocarcinoma and precancerous lesions with significantly worse overall survival and gender differences.Clinical and experimental gastroenterology · 2017Article
- Basis for molecular diagnostics and immunotherapy for esophageal cancer.Expert review of anticancer therapy · 2017Review
- Vitamin D Receptor Polymorphisms Are Associated with Reduced Esophageal Vitamin D Receptor Expression and Reduced Esophageal Adenocarcinoma Risk.Molecular medicine (Cambridge, Mass.) · 2015Article
- Article
- Vitamin D and GI cancers: shedding some light on dark diseases.Annals of translational medicine · 2014Review
- Vitamin D and the epidemiology of upper gastrointestinal cancers: a critical analysis of the current evidence.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Review
- Vitamin D receptor expression in the mucosal tissue at the gastroesophageal junction.Experimental and molecular pathology · 2012Article
- Vitamin D and gastrointestinal cancer.Journal of laboratory physiciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.